REVLIMID Archives - Express Pharma

Top 20 global biopharma companies report 1.6 per cent per cent market cap growth to $3.67 tn in 2023: GlobalData

Claims against Dr Reddy’s over Revlimid in US dismissed

Pfizer and BioNTech’s COVID-19 vaccine Comirnaty tops the list of best-selling drugs

Sun Pharma announces settlement of patent litigation for generic Revlimid in the US

Natco Pharma gets USFDA approval for lenalidomide capsules

Cipla settles patent litigation of Revlimid (lenalidomide) capsules with Celgene